ALMS (Alumis) Other Income (Expense) : $-5.52 Mil (TTM As of Sep. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Alumis Other Income (Expense)?

Alumis's other income expense for the Alumis's pretax income for the three months ended in Sep. 2024 was $-0.04 Mil. Its other income expense for the trailing twelve months (TTM) ended in Sep. 2024 was $-5.52 Mil.

Alumis Other Income (Expense) Historical Data

The historical data trend for Alumis's Other Income (Expense) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alumis Other Income (Expense) Chart

Alumis Annual Data

Trend

Dec22

Dec23

Other Income (Expense)

-0.07

-0.19

Alumis Quarterly Data
	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Other Income (Expense)	Get a 7-Day Free Trial			-0.57	-0.03	-3.11	-2.35	-0.04

Alumis Other Income (Expense) Calculation

Other income expense includes minority interest. Minority interest is a significant but non-controlling ownership of less than 50% of a company's voting shares by either an investor or another company.

Other Income (Expense) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.52 Mil.

Alumis (NAS:ALMS) Other Income (Expense) Explanation

Minority interest is reported on the consolidated income statement as a share of profit belonging to minority shareholders.

Alumis Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alumis Inc (NAS:ALMS) » Definitions » Other Income (Expense)

Comparable Companies

Traded in Other Exchanges

N/A

Address

280 East Grand Avenue, South San Francisco, CA, USA, 94080

Website

https://www.alumis.com

Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies.